<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90685">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01863953</url>
  </required_header>
  <id_info>
    <org_study_id>192024-082</org_study_id>
    <nct_id>NCT01863953</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine
      compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline, Day 42</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Average Eye Mean Diurnal IOP</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Average Eye Mean Diurnal IOP</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Eye Mean Diurnal IOP</measure>
    <time_frame>Day 14, Day 28, Day 42</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Fixed-Combination Bimatoprost/Brimonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine Tartrate Ophthalmic Solution 0.2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed-Combination Bimatoprost/Brimonidine</intervention_name>
    <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
    <arm_group_label>Fixed-Combination Bimatoprost/Brimonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost Ophthalmic Solution 0.01%</intervention_name>
    <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.</description>
    <arm_group_label>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</arm_group_label>
    <other_name>LUMIGAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Solution</intervention_name>
    <description>One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
    <arm_group_label>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Tartrate Ophthalmic Solution 0.2%</intervention_name>
    <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
    <arm_group_label>Brimonidine Tartrate Ophthalmic Solution 0.2%</arm_group_label>
    <other_name>ALPHAGAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ocular hypertension or glaucoma

          -  Requires intraocular pressure (IOP)-lowering therapy

        Exclusion Criteria:

          -  Cataract surgery in one eye

          -  Ocular laser or intraocular surgery within 6 months

          -  Refractive surgery in either eye

          -  Anticipated use of contact lenses during the study

          -  Expected use of artificial tears during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brimonidine</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
